Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 329993 in Rheumatoid Arthritis
NCT01414101Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2011
- Primary completion
- May 2013
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of ISIS-329993 in rheumatoid arthritis (RA), sponsored by Ionis Pharmaceuticals. Started Aug 2011; status: completed.
02
Drugs
ISIS-329993
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01414101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414101.